High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

(2015) Jean-Michel Molina et al.   LANCET

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Causes of death among HIV-infected patients in France in 2010 (national survey)

(2014) Philippe Morlat et al.   AIDS

Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial

(2014) L. Cotte et al.   CLINICAL INFECTIOUS DISEASES

Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study

(2014) Douglas Dieterich et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

(2014) Christophe Hézode et al.   GASTROENTEROLOGY

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

(2014) Christophe Hézode et al.   GUT

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

(2014) Hiromitsu Kumada et al.   HEPATOLOGY

Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis

(2014) Juan Berenguer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

(2014) Mark S. Sulkowski et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C

(2014) Jean-Pierre Bronowicki et al.   JOURNAL OF HEPATOLOGY

Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1

(2014) K. Kosaka et al.   JOURNAL OF VIRAL HEPATITIS

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

(2014) Michael Manns et al.   LANCET

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

(2014) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

(2013) Fiona McPhee et al.   HEPATOLOGY

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study

(2013) R Weber et al.   HIV MEDICINE

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

(2013) Anna S. Lok et al.   JOURNAL OF HEPATOLOGY

Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir

(2012) Fiona McPhee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir

(2012) Yoshiyasu Karino et al.   JOURNAL OF HEPATOLOGY

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

(2012) Yoshiyuki Suzuki et al.   JOURNAL OF HEPATOLOGY

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV–HCV-coinfected patients

(2011) Ana Treviño et al.   ANTIVIRAL THERAPY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients

(2011) P Trimoulet et al.   HIV MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE